Arcturus Therapeutics Holdings Inc.
Company Stats
- Market Cap
- $389.1M
- as of Sep 30, 2026
- Shares Outstanding
- 28.4M
- Free Float
- 95.0%
Income Statement
- Revenue
- $82.0M
- Operating Income
- -$76.3M
- Net Income
- -$65.8M
- EBITDA
- -$73.2M
- Revenue Growth, 3Y
- -26.4%
- FCF Margin, 3Y Avg
- -47.7%
- FCF Margin, Worst Year
- -90.8%
Cash Flow
- Free Cash Flow
- -$74.5M
- FCF Yield
- -19.1%
- Owner FCF Yield
- -25.7%
Balance Sheet
- Cash & Equivalents
- $230.9M
Returns & Capital
- SBC, 3Y Avg
- $32.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $82.0M | -$74.5M | -90.8% |
| FY2024 | $152.3M | -$60.4M | -39.7% |
| FY2023 | $166.8M | -$21.0M | -12.6% |
| FY2022 | $206.0M | $24.3M | 11.8% |
| FY2021 | $12.4M | -$138.4M | -1120.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back